Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 23,795,263
- Total 13F value
- $16,179,092
- Share change
- +1,267,057
- SEC-reported price per share
- $0.68
- Number of holders
- 35
- Value change
- +$854,217
- Number of buys
- 9
- Number of sells
- 16
- Shares outstanding
- 6,426,426
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
35
Top holders
10
XLO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Ownership snapshot
Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
AbbVie Inc.
Disclosed value leader
Yekaterina Chudnovsky
Comparable rows
1/15
Latest evidence
31 Mar 2025
13D/G
3/4/5
13F
Lead comparable stake: 9%
14 rows are not safely comparable across share classes.
13D/G row: AbbVie Inc.
Showing 1-6 of 15 holder rows.
Quick read
AbbVie Inc. leads the comparable SEC ownership view at 9%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens AbbVie Inc.'s linked filing trail.
Comparable ownership
Top 1
AbbVie Inc.
9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AbbVie Inc. |
13D/G
|
9%
Reported 13D/G
· 11 Feb 2025
|
$3,304,348
4,347,826 shares
|
$0 | 11 Feb 2025 |
| Yekaterina Chudnovsky |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$5,320,000
7,000,000 shares
|
— | 07 Jun 2024 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
—
denominator unverified
|
$3,308,202
4,566,817 shares
|
— | 31 Mar 2025 |
| SV7 Impact Medicine Fund LP |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$2,678,630
3,227,264 shares
|
— | 26 Oct 2021 |
| James E. Flynn |
3/4/5
Possible Member of 10% Group, 10%+ Owner
|
—
denominator unverified
|
$1,898,994
2,287,944 shares
|
— | 26 Oct 2021 |
| Atlas Venture Fund XI, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,762,629
2,754,109 shares
|
— | 08 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
35
Shares
23,795,263
Rows available
35
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2026 Across Filers
Q1 2026 holders
1
Q2 2025 holders
35
Holder diff
34
| Investor | Q1 2026 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend